Zealand Pharma A/S
ZEAL
Rank in Stocks
#5481
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Share Price
$35.84
Last synced: 2026-10-16
Market Cap
$2.49B
Change (1 day)
-1.27%
Change (1 year)
-49.95%
Country
DK
Trade Zealand Pharma A/S (ZEAL)
Category
Healthcare
Market Capitalization of Zealand Pharma A/S(ZEAL)
Market Cap: $2.49B
As of October 2026 Zealand Pharma A/S has a market cap of $2.49B. This makes Zealand Pharma A/S the world's 5481st most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Zealand Pharma A/S from 2013 to 2026
ZEAL compared with Top 5 Most Popular stocks
